Loxo Oncology and University of Colorado Cancer Center confirm Clinical Validation for LOXO-101 Against TRK Fusion Cancer Print E-mail
By William Kent   
Tuesday, 28 July 2015 20:08

Biopharmaceutical firm Loxo Oncology Inc. (NASDAQ:LOXO) and the University of Colorado Cancer Center has confirmed publication of research brief in online edition of journal Cancer Discovery showing the patient with tropomyosin receptor kinase fusion cancer enrolled in Phase 1 dose escalation trial of LOXO-101, only selective TRK inhibitor in clinical development.

 

 Other contributors to it include Knight Cancer Institute at Oregon Health & Science University as well as Foundation Medicine.

 

The peer-reviewed research brief gives description of female patient having advanced soft tissue sarcoma much metastatic to the lungs.

 

Robert C. Doebele, M.D., Ph.D., LOXO-101 clinical investigator, and University of Colorado Cancer Center member, opined that it is amazing to contemplate TRK fusions may collaborate a short but burgeoning list of actionable oncogenic drivers found across human cancer. He added that to see an unequivocal response in first TRK fusion patient gives early but encouraging validation of the target. 

 

Doebele added that it would be essential to see good results as more patients with TRK fusions are treated in future as well. The publication also gives details novel assays for evaluating LOXO-101's impact on TRK signaling as well as patient-derived TRK fusion models which show LOXO-101's TRK inhibition.

 

Jennifer Low, M.D., Ph.D., chief medical officer of Loxo Oncology, opined that TRK is more and more being impressive for the role in cancer biology and primary level of peer-reviewed clinical validation is a vital step ahead. Low added that the firm would continue in encouragingsafety and pharmacokinetics in the LOXO-101 Phase 1 trial.

 

Lara E. Davis, M.D., a medical oncologist and sarcoma specialist with the OHSU Knight Cancer Institute, opined that the firm’s aim is to understand better genetic drivers of sarcoma for improving treatment options for patients.

 

Shares of the company jumped 25% to $20.75.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter